BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Roche weaves $425M deal for 'suberbug' diagnostics firm
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Roche weaves $425M deal for 'suberbug' diagnostics firm
Aug. 14, 2015
By
Amanda Pedersen
No Comments
Roche AG wove a deal worth up to $425 million for Geneweave Biosciences Inc., a private U.S. diagnostics firm with technology aimed at fighting drug-resistant bacteria, which is considered one of health care's biggest threats.
BioWorld